New HIV shot candidates enter first human safety tests
NCT ID NCT06012136
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests the safety and tolerability of two experimental injectable drugs (capsid inhibitors) in 85 healthy adults. Participants receive a single dose or multiple doses of the drug or a placebo. The goal is to see if these drugs are safe enough to study further as a potential long-acting HIV treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VH4004280 and VH4011499 (capsid inhibitors)
What this could lead to
If successful, this could lead to a new long-acting injectable option for controlling HIV, reducing the need for daily pills.
What could go wrong
This is a very early Phase 1 safety study in healthy people, not those with HIV. It is too soon to know if these drugs will work against HIV or be safe long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Las Vegas, Nevada, 89113, United States
-
GSK Investigational Site
Austin, Texas, 78744, United States